News

The Duke EQAPOL/VQA team, led by Tom Denny in partnership with Dr. David Montefiori in the Department of Surgery, will implement a SARS-CoV-2 Neutralization Assay Concordance Survey (SNACS) in more than 50 participating laboratories worldwide.

DHVI is pleased to announce the approval of a Phase 1 clinical trial of one of our most promising antibody treatments for COVID-19.

The Duke University School of Medicine is expanding into a newly-leased research center in the Research Triangle Park (RTP). The 273,000 square foot facility in the Parmer RTP research and development campus, formerly home to pharmaceutical maker GlaxoSmithKline, is currently being renovated to accommodate School of Medicine faculty, staff and labs as soon as January 2021.

The COVID-19 pandemic has impacted laboratories across the world. Some laboratories have been labeled non-essential and face the challenges of being forcibly idled. Other laboratories have been labeled essential and face the challenge of keeping workers safe and delivering for their stakeholders during this crisis.

peculation that a vaccine for COVID-19 might be widely available by the end of this year is overly optimistic, three Duke experts said Wednesday.

Duke University’s School of Medicine research arm is building on its recent success in acquiring grants for immunology, infectious diseases and clinical trials with a move to Research Triangle Park.

The State of North Carolina enacted Session Law 2020-4, an Act to Provide Aid to North Carolinians in Response to the Coronavirus Disease 2019 Crisis, also known as the 2020 COVID-19 Recovery Act.

Panelists discussed a variety of topics including: drug trials and updates on the remdesivir and hydroxychloroquine studies, reports of possible vaccine progress, treating COVID in the ICU, public health policy, research on how the pandemic is progressing, safe re-openings, successful interventions and what still needs to be done.

The need for trusted knowledge and expertise is most valuable during a time of crisis. In response to the coronavirus, experts across Duke University and Duke Health have been critical in informing policymakers at the local, state, and national level. Scholars, doctors, and Duke administrators collaborate with policymakers every day, but have been increasingly engaged on public policy decisions as our nation responds to the unprecedented COVID-19 pandemic. 

When infected with SARS-CoV-2, why do some people—such as smokers and older adults— have extreme respiratory and cardiovascular distress while others have no symptoms at all?